Labeling Suit Costs Johnson & Johnson $63 Million

By Admin
A tragic reaction to a widely used medication – Childrens Motrin manufactured by Johnson & Johnson – caused a child to develop toxic ep...

A tragic reaction to a widely used medication – Children’s Motrin manufactured by Johnson & Johnson – caused a child to develop toxic epidermal necrolysis, eventually losing her sight and most of her skin in 2003.

Now, a jury has awarded the Massachusetts teenager and her parents a sum of $63 million over claims that the New Jersey-based multinational failed to provide adequate warnings of potential side effects on the medication’s label.

The extremely rare condition is usually caused by a reaction to drugs. Symptoms first include a fever before severely affecting the mucous membranes, leading to peeling skin covering the entire body.

Mystery Illness - Toxic Epidermal Necrolysis

The Jury’s decision reached Wednesday was met with protests from J&J’s McNeil consumer healthcare division and a statement read, “We disagree with today's verdict and are considering additional legal options. The Reckis family has suffered a tragedy and we sympathize deeply with them.” However, the company believes the label contains sufficient information on side effects and the cause of the teen’s conditions “are very rare conditions, and the specific cause is difficult to ascertain.”

The settlement awarded $50 million to the victim and $6.5 million to each of her parents.
 

Share

Featured Articles

PA Consulting: People Want 'Stackable' Healthcare Products

PA Consulting report shows people want ‘stackable’ personalised healthcare products and services that leverage personal data

HIV Testing Landmark Highlights Ongoing AIDS Problems

As US healthcare solutions specialist RMI passes the 350-million HIV testing kit mark, we look at the current HIV/AIDS situation globally

Schneider's Blum on Electricity 4.0 and Healthcare

Olivier Blum, EVP of Schneider Electric’s Energy Management business tells Healthcare Digital how Electricity 4.0 can improve people's wellbeing

Research Breakthrough Promises New Lupus Treatments

Medical Devices & Pharma

Healthcare Systems Worldwide Hit by Global IT Outage

Technology & AI

Abbott Labs' profits soar; Nipro opens First US Facility

Medical Devices & Pharma